Last reviewed · How we verify
Xenical
At a glance
| Generic name | Xenical |
|---|---|
| Also known as | Orlistat |
| Sponsor | Khoo Teck Puat Hospital |
| Target | Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Obesity
Common side effects
- Oily spotting
- Flatus with discharge
- Fecal urgency
- Fatty/oily stool
- Oily evacuation
- Increased defecation
- Fecal incontinence
- Gastrointestinal symptoms
- Hypoglycemia
- Abdominal distension
Serious adverse events
- Hepatic failure
- Hepatitis
- Increased transaminases
- Increased alkaline phosphatase
- Hypersensitivity reactions
- Angioedema
- Urticaria
- Rash
- Pruritus
Key clinical trials
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women (NA)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT (NA)
- Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (PHASE4)
- Weight Loss Management in Endometrial Cancer Survivors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |